The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2021.1924195
Abstract: Abstract Background and Objective: Nivolumab and Ipilimumab are immune checkpoint inhibitors. The combination of Nivolumab and Ipilimumab has been reported to have complementary effects in the treatment of metastatic melanoma. The combination therapy of Nivolumab… read more here.
Keywords: combination; efficacy safety; nivolumab; nivolumab combined ... See more keywords
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4598
Abstract: TPS4598Background: Over the past decade, treatment options for advanced RCC have evolved to include multiple agents targeting the vascular endothelial growth factor (VEGF) pathway. In addition, the... read more here.
Keywords: randomized open; phase randomized; nivolumab combined; open label ... See more keywords